| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
MPO/PR3 Panel
MessageFor Specimen Integrity during Extreme Weather see the “Lockbox Usage in Extreme Weather” document at the top of this page.
Test Code
MPOPR3
Alias/See Also
75850
CPT Codes
86021(2)
Includes
MPO and PR3
Preferred Specimen
1 mL Serum (SST or Red top)
Minimum Volume
0.5 mL
Instructions
Avoid hemolysis. Invert a minimum of 5 times then allow to clot in an upright position for 30 minutes. Centrifuge the tube for at least 10 minutes. Keep tightly stoppered.
Transport Container
SST (speckled top) tube
Transport Temperature
Room Temperature or Refrigerated (preferred)
Specimen Stability
Room Temperature = 1 day
Refrigerated = 8 days
Frozen = 8 days
Refrigerated = 8 days
Frozen = 8 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis, lipemia
Methodology
Enzyme Linked Immunosorbent Immunoassay (ELISA).
Setup Schedule
Monday, Tuesday and Thursday
Report Available
7 days
Clinical Significance
Autoantibodies to Myeloperoxidase (MPO) are commonly associated with Microscopic Polyangiitis, Churg-Strauss Syndrome, and Idiopathic, Paucimmune, Crescentic and Necrotizing Glomerulonephritis. These autoantibodies are clinically helpful in determining active versus inactive disease states. In monitoring the effect of therapy, and in evaluating the possibility of relapse in Microscopic Polyangiitis and its renal-limited variant.
Autoantibodies to Proteinase-3 (PR-3) may be seen in most patients with Wegener"s Granulomatosis. But also in 30% of patients with Microscopic Polyangiitis and Churge Strauss Syndrome. These autoantibodies are clinically helpful in determining active versus inactive disease states. In monitoring the effect of therapy and in evaluating the possibility of relapse.
Autoantibodies to Proteinase-3 (PR-3) may be seen in most patients with Wegener"s Granulomatosis. But also in 30% of patients with Microscopic Polyangiitis and Churge Strauss Syndrome. These autoantibodies are clinically helpful in determining active versus inactive disease states. In monitoring the effect of therapy and in evaluating the possibility of relapse.
Performing Laboratory
CompuNet Clinical Laboratories, LLC
2308 Sandridge Drive
Moraine, OH 45439
